Additional file 3 of A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models

Abstract

Additional file 3: Figure S3. Expression of CD74 after activation on T cell and B cell. T cells and B cells isolated from PBMCs of 3 healthy blood donors were either untreated (red) or activated (blue) by CD3/CD28 soluble antibodies and IL-2 for T cells, and LPS (10 ng/mL)/ anti-IgM (10 µg/mL) for B cells. One representative of 3 healthy blood donors was shown